68Ga PSMA PET/MR in the differentiation of low and high grade gliomas: Is 68Ga PSMA PET/MRI useful to detect brain gliomas?

Akgün, Elife; Akgün, Mehmet Yiğit; Selçuk, Hatem Hakan; Uzan, Mustafa; Sayman, Haluk

doi:10.1016/j.ejrad.2020.109199

Cited by 9 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 209 records were identified and screened through the comprehensive literature search described above. Taking into account predefined eligibility criteria, these 209 records were assessed for eligibility and 201 records were excluded (178 as not in the field of interest, 6 as reviews, editorials, or letters, and 17 as case reports); 8 remaining articles were judged as eligible for inclusion in the systematic review (qualitative synthesis) after full-text assessment [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. No additional studies were eligible for inclusion after screening the references of these articles.…”

Section: Resultsmentioning

confidence: 99%

“…No additional studies were eligible for inclusion after screening the references of these articles. Six out of eight articles were included in the meta-analysis (quantitative synthesis) [ 20 , 21 , 22 , 23 , 25 , 26 ]; two studies included in the systematic review were excluded from the meta-analysis [ 24 , 27 ] due to possible partial patient data overlap with other studies of the same research group. Figure 1 summarizes the study selection process.…”

Section: Resultsmentioning

confidence: 99%

“…Diagnostic accuracy data of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HGG patients for each study are listed in Table 4 . Overall, the index test has demonstrated an excellent diagnostic performance in detecting HGG in all studies included in the systematic review, both on a per patient- and on a per lesion-based analysis and in different clinical settings (at initial diagnosis and in the suspicious recurrence after treatment) [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Moreover, PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals was very useful in detecting multifocal disease in HGG patients [ 20 , 21 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

“…In the setting of initial diagnosis of gliomas, compared to LGG, HGG are usually characterized by increased PSMA-targeting radiopharmaceutical uptake [ 22 , 23 ]. Average TBR in HGG ranged from 11.52 to 13.95 and average TBR in LGG ranged from 1.29 to 3.42 [ 22 , 25 ].…”

Section: Resultsmentioning

confidence: 99%

“…Average TBR in HGG ranged from 11.52 to 13.95 and average TBR in LGG ranged from 1.29 to 3.42 [ 22 , 25 ]. Tumor grade and proliferation index (Ki-67) in patients with glioma were found to have a correlation with uptake of PSMA-targeting radiopharmaceuticals [ 22 , 23 , 25 ]. The index test was more sensitive than MRI in distinguishing HGG from LGG, even if there was no statistically significant difference among their specificities [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background: Several studies proposed the use of positron emission tomography (PET) with Prostate Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in brain tumors. Our aim is to calculate the diagnostic accuracy of these methods in high-grade gliomas (HGG) with a bivariate meta-analysis. Methods: A comprehensive literature search of studies on the diagnostic accuracy of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HGG was performed. Original articles evaluating these imaging methods both in the differential diagnosis between HGG and low-grade gliomas (LGG) and in the assessment of suspicious HGG recurrence were included. Pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-), and diagnostic odds ratio (DOR) including 95% confidence intervals (95% CI) were calculated. Statistical heterogeneity was also assessed using the I2 test. Results: The meta-analysis of six selected studies (157 patients) provided the following results about PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in the diagnosis of HGG: sensitivity 98.2% (95% CI: 75.3–99.9%), specificity 91.2% (95% CI: 68.4–98.1%), LR+ 4.5 (95% CI: 2.2–9.3), LR− 0.07 (95% CI: 0.04–0.15), and DOR 70.1 (95% CI: 19.6–250.9). No significant statistical heterogeneity among the included studies was found (I2 = 0%). Conclusions: the quantitative data provided demonstrate the high diagnostic accuracy of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals for HGG detection. However, more studies are needed to confirm the promising role of PSMA-targeted PET in this clinical setting.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

Simultaneously acquired rSUV and rCBF of 18F-FDG/MRI in peritumoral brain zone can help to differentiate the grade of gliomas

Qu,

Zeng,

Hang

et al. 2023

Meta-Radiology

View full text Add to dashboard Cite

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

et al. 2022

View full text Add to dashboard Cite

Introduction. Positron emission tomography (PET) imaging with prostate-specific membrane antigen- (PSMA-) binding tracers has been found incidentally to demonstrate uptake in CNS tumors. Following the encouraging findings of several such case reports, there is a growing interest in the potential application of PSMA-targeted PET imaging for diagnostics, theranostics, and monitoring of CNS tumors. This is a systematic literature review on PSMA-binding tracers in CNS tumors. Methods. A PubMed search was conducted, including preclinical and clinical reports. One hundred and twelve records were identified, and after screening, 56 were included in the final report. Results. Tissue studies demonstrated PSMA expression in tumor vascular endothelial cells, without expression in normal brain tissue, though the extent and intensity of staining varied by anti-PSMA antibody and methodology. Most included studies reported on gliomas, which showed strong PSMA ligand uptake and more favorable tumor to background ratios than other PET tracers. There are also case reports demonstrating PSMA ligand uptake in prostate cancer brain metastases, nonprostate cancer brain metastases, and meningiomas. We also review the properties of the various PSMA-binding radiotracers available. Therapeutic and theranostic applications of PSMA-binding tracers have been studied, including labeled alpha- and beta-ray emitting isotopes, as well as PSMA targeting in directing MRI-guided focused ultrasound. Conclusions. There is a potential application for PSMA-targeted PET in neuro-oncology as a combination of diagnostic and therapeutic use, as a theranostic modality for managing CNS tumors. Further research is needed regarding the mechanism(s) of PSMA expression in CNS tumors and its differential performance by tumor type.

show abstract

68Ga PSMA PET/MR in the differentiation of low and high grade gliomas: Is 68Ga PSMA PET/MRI useful to detect brain gliomas?

Cited by 9 publications

References 8 publications

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis

Simultaneously acquired rSUV and rCBF of 18F-FDG/MRI in peritumoral brain zone can help to differentiate the grade of gliomas

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

Contact Info

Product

Resources

About